comparemela.com

Latest Breaking News On - Pending health canada - Page 4 : comparemela.com

Adastra Holdings Enters Market with Creation of THC-Free 99% Pure CBD Isolate

Adastra Holdings Enters Market with Creation of THC-Free 99% Pure CBD Isolate
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

Adastra Holdings Completes Acquisition of Phyto Extractions

Adastra Holdings Completes Acquisition of Phyto Extractions
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

Adastra Holdings Announces Record Sales in August

Adastra Holdings Announces Record Sales in August
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

Adastra Holdings CEO Provides Corporate Update

Adastra Holdings CEO Provides Corporate Update
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

Aptorum Group announces submission of Clinical Trial Application

Aptorum Group announces submission of Clinical Trial Application 22nd December 2020     Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA). Pending Health Canada’s approval, the Phase 1 trial is designed to test the safety, tolerability and pharmacokinetics of ALS-4 in healthy volunteers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.